Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
Authors
Razia Aslam
RCSI Education and Research Centre, Dublin, AL, Ireland;
Razia Aslam , Bryan T Hennessy , Sinead Toomey , Catherine Richards
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 167)
DOI
10.1200/JCO.2023.41.4_suppl.167
Abstract #
167
Poster Bd #
J7
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Preclinical drug testing for clinical trial planning of novel combinative therapy with PI3K and MAPK inhibitors in colorectal cancer(CRC).
First Author: Cha Len Lee
Poster
2023 ASCO Annual Meeting
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
First Author: Jesús Fuentes Antrás
Poster
2023 ASCO Annual Meeting
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
First Author: Laurien Joanna Zeverijn
Poster
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
First Author: Sanne Huijberts